Residual kidney function (RKF) is an important factor influencing both technique and patient survival in peritoneal dialysis (PD) patients. B-type natriuretic peptide (BNP) is considered a marker of cardio-renal syndrome. The relationship between BNP and RKF in PD patients remains unclear.
Methods
We conducted a prospective study of 89 patients who had started and continued PD for 6 months or more in Kyushu University Hospital between June 2006 and September 2015. Participants were divided into low BNP (≤ 102.1 ng/L) and high BNP (> 102.1 ng/L) groups according to median plasma BNP level at PD initiation. The primary outcome was RKF loss, defined as 24-hour urine volume less than 100 mL. We estimated the association between BNP and RKF loss using a Kaplan-Meier method and Cox proportional hazards model and compared the rate of RKF decline between the 2 groups. To evaluate the consistency of the association, we performed subgroup analysis stratified by baseline characteristics.
Results
During the median follow-up of 30 months, 30 patients lost RKF. Participants in the high BNP group had a 5.87-fold increased risk for RKF loss compared with the low BNP group after adjustment for clinical and cardiac parameters. A high plasma BNP level was more clearly associated with RKF loss in younger participants compared with older participants in subgroup analysis.
Conclusions
B-type natriuretic peptide may be a useful risk marker for RKF loss in PD patients. The clinical importance of plasma BNP level as a marker of RKF loss might be affected by age.
LiaoC.T., ChenY.M., ShiaoC.C., HuF.C., HuangJ.W., KaoT.W.Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis.Nephrol Dial Transplant2009; 24: 2909–14.
2.
TermorshuizenF., KorevaarJ.C., DekkerF.W., van ManenJ.G., BoeschotenE.W., KredietR.T.The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2.Am J Kidney Dis2003; 41: 1293–302.
3.
SzetoC.C., LaiK.N., WongT.Y., LawM.C., LeungC.B., YuA.W.Independent effects of residual renal function and dialysis adequacy on nutritional status and patient outcome in continuous ambulatory peritoneal dialysis.Am J Kidney Dis1999; 34: 1056–64.
4.
PerlJ., BargmanJ.M.The importance of residual kidney function for patients on dialysis: a critical review.Am J Kidney Dis2009; 53: 1068–81.
5.
SzetoC.C., KwanB.C., ChowK.M., ChungS., YuV., ChengP.M.Predictors of residual renal function decline in patients undergoing continuous ambulatory peritoneal dialysis.Perit Dial Int2015; 35: 180–8.
6.
BernardoA., FonsecaI., RodriguesA., CarvalhoM.J., CabritaA.Predictors of residual renal function loss in peritoneal dialysis: is previous renal transplantation a risk factor?Adv Perit Dial2009; 25: 110–4.
7.
HtayH., ChoY., PascoeE.M., DarssanD., HawleyC., JohnsonD.W.Predictors of residual renal function decline in peritoneal dialysis patients: the balANZ trial.Perit Dial Int2017; 37: 283–9.
8.
JohnsonD.W., MudgeD.W., SturtevantJ.M., HawleyC.M., CampbellS.B., IsbelN.M.Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.J Am Soc Nephrol2012; 23: 1097–107.
9.
SheenV., BhallaV., Tulua-TataA., BhallaM.A., WeissD., ChiuA.The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease.Am Heart J2007; 153: 244.e1–5.
10.
NaganumaT., SugimuraK., WadaS., YasumotoR., SugimuraT., MasudaC.The prognostic role of brain natriuretic peptides in hemodialysis patients.Am J Nephrol2002; 22: 437–44.
11.
SivalingamM., VilarE., MathavakkannanS., FarringtonK.The role of natriuretic peptides in volume assessment and mortality prediction in haemodialysis patients.BMC Nephrol2015; 16: 218.
12.
IshigamiJ., IimoriS., KuwaharaM., SasakiS., TsukamotoY.Diagnostic value of B-type natriuretic peptide for estimating left atrial size and its usefulness for predicting all-cause mortality and cardiovascular events among chronic haemodialysis patients.Nephrology (Carlton)2014; 19: 777–83.
13.
PaniaguaR., AmatoD., MujaisS., VoneshE., RamosA., Correa-RotterR.Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial.Clin J Am Soc Nephrol2008; 3: 407–15.
JoisP., MebazaaA.Cardio-renal syndrome type 2: epidemiology, pathophysiology, and treatment.Semin Nephrol2012; 32: 26–30.
16.
RoncoC., McCulloughP., AnkerS.D., AnandI., AspromonteN., BagshawS.M.Cardio-renal syndromes: report from the Consensus Conference of the Acute Dialysis Quality Initiative.Eur Heart J2010; 31: 703–11.
17.
VasanR.S.Biomarkers of cardiovascular disease: molecular basis and practical considerations.Circulation2006; 113: 2335–62.
18.
YoshitomiR., NakayamaM., SakohT., FukuiA., ShikuwaY., TominagaM.Plasma B-type natriuretic peptide concentration is independently associated with kidney function decline in Japanese patients with chronic kidney disease.J Hypertens2016; 34: 753–61.
19.
SpanausK.S., KronenbergF., RitzE., SchlapbachR., FliserD., HersbergerM.B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study.Clin Chem2007; 53: 1264–72.
Working Group Committee for Preparation of Guidelines for Peritoneal Dialysis, Japanese Society for Dialysis Therapy. 2009. Japanese Society for Dialysis Therapy guidelines for peritoneal dialysis.Ther Apher Dial2010; 14: 489–504.
22.
DevereuxR.B., ReichekN.Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method.Circulation1977; 55: 613–8.
23.
WangY., MossJ., ThistedR.Predictors of body surface area.J Clin Anesth1992; 4: 4–10.
24.
TeichholzL.E., KreulenT., HermanM.V., GorlinR.Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy.Am J Cardiol1976; 37: 7–11.
25.
GuoQ., YiC., LiJ., WuX., YangX., YuX.Prevalence and risk factors of fluid overload in Southern Chinese continuous ambulatory peritoneal dialysis patients.PLOS One2013; 8: e53294.
26.
HungS.C., KuoK.L., PengC.H., WuC.H., LienY.C., WangY.C.Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease.Kidney Int2014; 85: 703–9.
27.
TianN., GuoQ., ZhouQ., CaoP., HongL., ChenM.The impact of fluid overload and variation on residual renal function in peritoneal dialysis patient.PLOS One2016; 11: e0153115.
28.
LiangF., GardnerD.G.Autocrine/paracrine determinants of strain-activated brain natriuretic peptide gene expression in cultured cardiac myocytes.J Biol Chem1998; 273: 14612–9.
29.
RichardsA.M., CrozierI.G., HolmesS.J., EspinerE.A., YandleT.G., FramptonC.Brain natriuretic peptide: natriuretic and endocrine effects in essential hypertension.J Hypertens1993; 11: 163–70.
30.
RusterC., WolfG.Renin-angiotensin-aldosterone system and progression of renal disease.J Am Soc Nephrol2006; 17: 2985–91.
31.
HeQ., WuG., LapointeM.C.Isoproterenol and cAMP regulation of the human brain natriuretic peptide gene involves Src and Rac.Am J Physiol Endocrinol Metab2000; 278: E1115–23.
32.
HanfordD.S., ThueraufD.J., MurrayS.F., GlembotskiC.C.Brain natriuretic peptide is induced by alpha 1-adrenergic agonists as a primary response gene in cultured rat cardiac myocytes.J Biol Chem1994; 269: 26227–33.
33.
Beretta-PiccoliC., WeidmannP., SchifflH., CottierC., ReubiF.C.Enhanced cardiovascular pressor reactivity to norepinephrine in mild renal parenchymal disease.Kidney Int1982; 22: 297–303.
34.
IshiiM., IkedaT., TakagiM., SugimotoT., AtarashiK., IgariT.Elevated plasma catecholamines in hypertensives with primary glomerular diseases.Hypertension1983; 5: 545–51.
EriguchiM., TsuruyaK., HaruyamaN., YamadaS., TanakaS., SuehiroT.Renal denervation has blood pressure-independent protective effects on kidney and heart in a rat model of chronic kidney disease.Kidney Int2015; 87: 116–27.
37.
AdamczakM., ZeierM., DikowR., RitzE.Kidney and hypertension.Kidney Int Suppl2002: 62–7.
38.
LokeI., SquireI.B., DaviesJ.E., NgL.L.Reference ranges for natriuretic pep-tides for diagnostic use are dependent on age, gender and heart rate.Eur J Heart Fail2003; 5: 599–606.
39.
PfistererM., BuserP., RickliH., GutmannM., ErneP., RickenbacherP.BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) randomized trial.JAMA2009; 301: 383–92.
40.
JourdainP., JondeauG., FunckF., GueffetP., Le HellocoA., DonalE.Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study.J Am Coll Cardiol2007; 49: 1733–9.
